Reviva Pharmaceuticals
Develops brilaroxazine-led therapies for CNS, inflammatory, and cardiometabolic diseases.
Something off on this page? Send us feedback.
Profile
Reviva is a late-stage biotechnology company developing brilaroxazine for schizophrenia and other CNS-related indications, with RP1208 as an earlier pipeline asset. FDA feedback has put a second registrational phase 3 schizophrenia trial on the critical path before a possible NDA.
Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on internally discovered drug candidates for central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline is led by brilaroxazine, also known as RP5063, an oral dopamine-serotonin modulator being developed primarily for acute and maintenance schizophrenia.
Reviva also lists potential neuropsychiatric extensions, respiratory indications such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis, topical psoriasis work, and RP1208 for depression and obesity. In March 2026, the company said FDA feedback called for a second registrational phase 3 trial before a possible brilaroxazine NDA, and it planned RECOVER-2 activities for 2026. Reviva has no approved commercial product; its path depends on clinical execution, regulatory review, manufacturing readiness, patents, and access to additional capital.
Company facts
Key statistics
Year to date −91.6% · Average volume (30d) 42.1K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.39 | −$0.19 | +50.6% | — | — | — | +1.10% |
| Aug 12, 2026Q2 FY26 | −$0.39 | −$0.19 | +50.6% | — | — | — | +9.55% |
| May 14, 2026Q1 FY26 | −$0.75 | −$0.46 | +38.7% | — | — | — | −14.74% |
| Mar 30, 2026Q4 FY25 | −$1.08 | $0.72 | +166.7% | — | — | — | +10.56% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$6.5M | −$6.1M | −$4.0M | −$3.6M | −$3.3M | −$2.62T | |
| Net income | −$6.4M | −$6.1M | −$4.0M | −$3.4M | −$3.2M | −$2.45T | |
| Diluted EPS | −$2.60 | −$2.40 | −$1.10 | −$5.21 | −$0.46 | −$0.19 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $19.89T · Total debt $144.09B · Total assets $21.14T · Shareholders' equity $15.21T
Dividends
No dividends on record.
Ownership
Shares outstanding 12.81M · Float 12.27M · 95.8% free float
Insiders — no current Form 4 position.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Integrated Core Strategies (US) LLC | 794.0K | 6.20% | 13G | Mar 30, 2026 |
| Barclays PLC | 763.6K | 5.96% | 13G | May 14, 2026 |
| UBS Group AG | 746.1K | 5.80% | 13G | May 7, 2026 |
| Emc Capital Management | 6.7K | 0.05% | 13F | Jul 29, 2026 |
| TD Waterhouse Canada Inc. | 625 | 0.00% | 13F | Jul 27, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
Not reported.